Thus, patients whose HbA1c is lowered with the combination of sotagliflozin and insulin are less likely to experience hypoglycemia than those whose HbA1c reductions of a similar magnitude are achieved with insulin intensification alone. The gene discussed is INS; the disease is Hypoglycemia.